Zai Lab (Shanghai) Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Zai Lab (Shanghai) Co. sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Zai Lab (Shanghai) Co.: 5 sponsored US clinical trials, 4 recruiting.
Zai Lab (Shanghai) Co. sponsors 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.
Upper-quartile sponsor footprint
Zai Lab (Shanghai) Co. sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
NCT07374848
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
A Trial of ZL-1201 in Subjects With Advanced Cancer
NCT04257617
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Zai Lab (Shanghai) Co. pipeline
4 recruiting of 5 indexed (80% open); 1 completed (20%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Zai Lab (Shanghai) Co.: open-pipeline peers nationwide
Peers matched on 5 registered trials and 80% open enrollment, not the therapeutic-area sidebar.
Zai Lab (Shanghai) Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 80% open enrollment (± trial volume)
- Alpha Tau Medical · 80% recruiting · 5 trials
- Buck Institute for Research on Aging · 80% recruiting · 5 trials
- IDEAYA Biosciences · 80% recruiting · 10 trials
- MapLight Therapeutics · 80% recruiting · 5 trials
Related
What to do with this Zai Lab (Shanghai) Co. page
5 registered trials is a research-attention snapshot, not an endorsement of Zai Lab (Shanghai) Co. or any single study.
- 4 of Zai Lab (Shanghai) Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Solid Tumors is the condition Zai Lab (Shanghai) Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Zai Lab (Shanghai) Co. pipeline card: 5 registered trials from official public datasets.Report a data error.